Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States

BACKGROUND: Real-world assessments of biosimilars are needed to understand their effectiveness and safety in practice settings that may differ from those seen in clinical trials or healthcare systems in different countries. To assess the effectiveness and safety of a biosimilar (infliximab-dyyb) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Joshua T, Velayos, Fernando S, Niu, Fang, Liu, Vincent, Delate, Thomas, Pola, Suresh, Le, Kim, Hui, Rita L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802363/
https://www.ncbi.nlm.nih.gov/pubmed/36776661
http://dx.doi.org/10.1093/crocol/otab051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802363/
https://www.ncbi.nlm.nih.gov/pubmed/36776661
http://dx.doi.org/10.1093/crocol/otab051

Ejemplares similares